Patent · US Active

Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands

US7863291B2 · kind B2 · utility

15Cited by

1References

14Claims

0Family size

Assignee

Bristol-Myers Squibb Company · US

Inventors

James H. Cook, II · East Hampton, US
Ivar M. McDonald · East Haddam, US
Dalton King · Hamden, US
Richard E. Olson · Wilmington, US
Nenghui Wang · Guilford, US
Christiana I. Iwuagwu · Wallingford, US
F. Christopher Zusi · Williamsville, US
John E. Macor · Guilford, US

Key dates

Filing date	Apr 14, 2009
Grant date	Jan 4, 2011
Priority date	—
Expiry date	Apr 14, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.